Results 141 to 150 of about 176,622 (333)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis [PDF]

, 2018
Alessandro Ottaiano, Alfonso De Stefano, Monica Capozzi, Anna Nappi, Chiara De Divitiis, Carmela Romano, Lucrezia Silvestro, Antonino Cassata, Rossana Casaretti, Salvatore Tafuto, Michele Caraglia, Massimiliano Berretta, Guglielmo Nasti, Antonio Avallone   +13 more
openalex   +1 more source

Mobocertinib and Bevacizumab for Amivantamab-Refractory Lung Cancer With EGFR Exon 20 Insertion Mutation: A Case Report

, 2023
Jae Min Kim, Youngjoo Lee
openalex   +1 more source

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study [PDF]

, 2023
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, Takeshi Kawakami, Yusuke Onozawa, Kazunori Honda, Shigenori Kadowaki, Yukiya Narita, Takahiro Tsushima, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Masashi Ando, Keita Mori, Hiromichi Shirasu, Hirofumi Yasui, Kei Muro   +16 more
openalex   +1 more source

Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy. Methods A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Joshua S Cheruvathur, Gabriel Levin, Reitan Ribeiro, Florentin Racovitan, Joanne Power, Xing Zeng, John Sampalis, Lucy Gilbert   +7 more
wiley   +1 more source

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

Journal for ImmunoTherapy of Cancer
Background Options remain limited for patients requiring later lines of therapy for metastatic non-small cell lung cancer (mNSCLC) due to poor prognosis and potential toxicities.
Enriqueta Felip, Francois Ghiringhelli, Alona Zer, Byoung Chul Cho, Sun Min Lim, Laurent Greillier, Alastair Greystoke, Nuria Pardo, Yaacov R Lawrence, Nedal Al-Sakaff, Hans-Joachim Helms, Hen Prizant, Jan Pintoffl, Farah Louise Lim   +13 more
doaj   +1 more source

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Biologics: Targets & Therapy, 2008
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States.
Mary F Mulcahy
doaj  

Emerging Role of MRI‐Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer, with significant variability in patient outcomes even within the same stage according to the Barcelona Clinic Liver Cancer staging system. Accurately predicting patient prognosis and potential treatment response prior to therapy initiation is crucial for ...
Feng Che, Jing Zhu, Qian Li, Hanyu Jiang, Yi Wei, Bin Song   +5 more
wiley   +1 more source

Treatment Strategy and Residual Disease as Determinants of Survival in Stage IVB High‐Grade Serous Ovarian Cancer: A Retrospective Cohort Study

Journal of Surgical Oncology, EarlyView.
ABSTRACT Background and Objective Stage IVB high‐grade serous ovarian cancer (HGSOC) carries a poor prognosis. We aimed to: (1) describe the characteristics and survival of patients treated with primary cytoreductive surgery (PCS), interval cytoreductive surgery (ICS) or chemotherapy alone, (2) investigate the correlation between disease distribution ...
Anouk Benseler, Adina Tanen, Taymaa May, Lisa Avery, Genevieve Bouchard‐Fortier, Marcus Q. Bernardini, Liat Hogen   +6 more
wiley   +1 more source

USP28 Promotes Osimertinib Resistance in H1975 NSCLC Cells by Deubiquitinating and Stabilizing SIRT1

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Osimertinib (OSI) resistance in non‐small cell lung cancer (NSCLC) remains a significant challenge. This report explored the precise role of USP28 on OSI resistance in NSCLC and identified a functional downstream effector. OSI‐resistant H1975 cells (H1975/OSI) were established by long‐term OSI exposure.
Hu‐Sen Fan, Xiu‐Mei Li, Jia‐Qi Gu, Hai‐Feng Wang, Zhen‐Jiang Zhang   +4 more
wiley   +1 more source